Response Biomedical (V.RBM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Response Biomedical (V.RBM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Christopher Millard who started this subject	6/23/2001 12:38:03 AM
From: Dick Martin	of 655

Completes Patient Enrollment To Pave Way For FDA Application 6/21/01 RESPONSE BIOMEDICAL CORP ("RBM-V") - Completes Patient Enrollment To Pave Way For FDA Application Response Biomedical Corp. is pleased to announce that it has completed patient enrollment in the clinical trial of the RAMP Reader and diagnostic use of a RAMP assay for the quantitative determination of myoglobin in whole blood. Myoglobin is a cardiac marker that is used in the diagnosis of a heart attack. The Company is on target to file regulatory submissions with the United States and Canadian regulatory agencies by the end of June. Response Biomedical undertook a multi-center clinical trial for the RAMP Reader and RAMP myoglobin assay from mid March to early June 2001. Response Biomedical is currently preparing separate regulatory submissions for the RAMP Reader and the myoglobin test for the FDA and the Canadian Therapeutic Product Directive, with regulatory clearances in the US and Canada anticipated by September 30, 2001. "We are on target to meet the most significant milestone in the Company's history," said Bill Radvak, Response Biomedical President and CEO. "We are confident that the clinical test results support our claims as to the accuracy of RAMP, and look forward to fulfilling our commitment to our shareholders to have the applications submitted by June 30." Response Biomedical develops quantitative, point-of-care, diagnostic tests for use with its proprietary RAMP System. The RAMP System reduces the cost of healthcare by allowing accurate, rapid and easy-to-use tests to be performed in hospitals, clinics, laboratories and physicians offices worldwide. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. The statements made in this press release may contain certain forward-looking statements that involve a number of risks and uncertainties. Actual events or results may differ from the Company's expectations. TEL: (604) 681-4101 John Gomez, Corporate Communications Manager FAX: (604) 412-9830 Email: jgomez@responsebio.com Website: www.responsebio.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next